Company Quick10K Filing
Harpoon Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 25 $299
10-K 2020-03-12 Annual: 2019-12-31
10-Q 2019-11-06 Quarter: 2019-09-30
10-Q 2019-08-05 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-03-14 Annual: 2018-12-31
S-1 2018-12-27 Public Filing
8-K 2020-03-12 Earnings, Exhibits
8-K 2019-12-20 Enter Agreement
8-K 2019-11-20 Regulation FD, Exhibits
8-K 2019-11-06 Earnings, Exhibits
8-K 2019-08-05 Earnings, Exhibits
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-03-14 Earnings, Exhibits
8-K 2019-02-12 Amend Bylaw, Other Events, Exhibits

Harpoon Therapeutics Financials

HARP Metrics, Comps, Filings

Annual | Quarterly

Business

We are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using our proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, we are developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Since commencing operations in 2015, we have created four TriTAC product candidates, each of which we expect to be in clinical development by the end of 2020. Our lead TriTAC product candidate, HPN424, is currently in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. In January 2019, we announced preliminary data from this trial that supports the proposed mechanism of action of HPN424. Our second TriTAC product candidate, HPN536, is expected to enter clinical development in the first half of 2019 for the treatment of ovarian cancer and other MSLN-expressing solid tumors.

In January 2019, we announced preliminary data from seven patients who had been enrolled in our Phase 1 clinical trial of HPN424, as of December 31, 2018. Safety and tolerability are the primary objectives of the trial and as of December 31, 2018, all seven patients remained on the study, receiving weekly treatments of HPN424 with no dose limiting toxicities. Our secondary objectives include pharmacokinetic and pharmacodynamic data, as well as preliminary anti-tumor activity. The clinical trial results to date include measurement of HPN424 serum exposure that supports weekly dosing and changes in cell and serum biomarkers consistent with T cell activation.

Our TriTACs are designed to advance the therapeutic potential of T cell engagers, an established and meaningful mechanism of action. The first bi-specific T cell engager, or BiTE, to be approved by the FDA was, Amgen's Blincyto. Blincyto was approved in 2014 as a monotherapy for the treatment of acute lymphoblastic leukemia. Since then, other BiTEs have shown promising therapeutic potential in clinical trials. We developed our proprietary TriTAC platform to incorporate the strengths of BiTEs and improve upon their critical shortcomings, such as a short half life. We believe our TriTAC platform offers the following features for the discovery and development of novel immunotherapies for the treatment of a wide array of diseases, including cancer:


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Fellazo (FLLZ) 345,056 -2,070.3 -807% 21 680 0 0 -167 -167 345,056
Kraig Biocraft Laboratories (KBLB) 342,651 0% -263.9 -124% 1,276 5,343 141 0 -1,582 -1,296 341,977
ETFS Silver Trust (SIVR) 337,258 28.0 4% 334,676 83 0 0 12,035 12,035 337,258
Kaleido Biosciences (KLDO) 335,102 -5.7 -41% 109,997 25,371 0 0 -44,858 -43,716 247,815
Avedro (AVDR) 334,795 73% -20.6 -20% 78,952 28,911 19,062 13,997 -15,781 -14,375 296,719
New York & Company (NWY) 330,378 30% 171.7 -2% 488,888 421,105 860,882 261,954 -11,662 1,439 247,058
NextCure (NXTC) 325,730 0% -10.1 -7% 213,050 34,455 2,759 0 -14,376 -13,132 133,002
Invesco DB US Dollar Index Bullish Fund (UUP) 322,276 14.1 7% 328,380 6,445 0 0 22,846 22,873 322,228
SciPlay (SCPL) 311,217 66% 9.6 8% 337,000 116,400 118,100 77,600 26,200 27,300 260,817
Corium (CORI) 305,900 0% -4.9 -50% 112,131 87,239 37,693 0 -56,540 -45,465 223,763
Exantas Capital (RSO) 303,720 0% 19.4 1% 2,519,737 1,961,785 60,298 0 35,602 113,727 2,203,721
Energy XXI Gulf Coast (EGC) 300,174 0% -1.3 -30% 1,032,246 929,173 454,101 0 -313,739 -174,942 228,492
Harpoon Therapeutics (HARP) 299,111 0% -6.7 -16% 157,016 34,543 3,189 0 -25,396 -24,796 165,211
Zynex (ZYXI) 295,052 81% 21.5 45% 21,839 7,772 38,026 30,679 9,725 13,285 284,998
Focus Universal (FCUV) 294,910 60% -164.9 -19% 9,067 600 691 411 -1,768 -1,768 291,485
South Plains Financial (SPFI) 292,151 -3.7 0% 2,777,170 2,486,057 0 0 10,853 31,316 -115,965
Invesco DB Oil Fund (DBO) 289,332 -4.0 -25% 290,354 4,765 0 0 -72,365 -72,287 289,232
Parker Drilling (PKD) 277,425 10% -5.6 -28% 707,911 358,753 565,971 56,953 -199,631 -62,102 347,434
Fortem Resources (FTMR) 276,706 -190.3 -18% 7,892 1,291 0 0 -1,384 -1,454 276,646
Sonim Technologies (SONM) 263,662 34% -25.0 -14% 85,913 50,835 70,231 24,189 -12,289 -10,462 261,650

Balance Sheet ($'000)2018-12-31
Cash467
Accounts Receivable
Inventory
PP&E2,998
Assets102,580
Accounts Payable4,357
Long-Term Debt0
Liabilities26,482
Stockholders' Equity-53,479
Income Statement ($'000)2018-12-31
Revenue4,750
Cost of Revenue
Gross Profit
R&D26,368
SG&A6,106
Tax0
Net Income-27,366
Cash Flow ($'000)2018-12-31
Cash Operating-27,126
Cash Investing-663
Cash Financing88,326